Black men with advanced prostate cancer less likely to receive crucial treatment, UCLA study finds

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that Black men diagnosed with more advanced stages of prostate cancer are significantly less likely to be prescribed novel hormone therapy than other racial and ethnic groups—including white or Latino men—despite the therapy being proven to effectively control the growth of prostate tumors and extend the lives of men with the disease.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases. 
When Helene Brown, a cancer control pioneer who jokingly described herself as “the first in a long line of political oncologists,” delivered the keynote address at the Oncology Nursing Society annual meeting in 1990, she set forth bold predictions for the ensuing 20 years of the field: appointments conducted over “computerphone,” major genetic breakthroughs, and universal healthcare.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login